JP2008500279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500279A5 JP2008500279A5 JP2006554230A JP2006554230A JP2008500279A5 JP 2008500279 A5 JP2008500279 A5 JP 2008500279A5 JP 2006554230 A JP2006554230 A JP 2006554230A JP 2006554230 A JP2006554230 A JP 2006554230A JP 2008500279 A5 JP2008500279 A5 JP 2008500279A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- peptide
- cell
- endogenously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54676404P | 2004-02-23 | 2004-02-23 | |
| US60/546,764 | 2004-02-23 | ||
| PCT/US2005/005198 WO2005082939A2 (en) | 2004-02-23 | 2005-02-17 | Anti-abeta antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500279A JP2008500279A (ja) | 2008-01-10 |
| JP2008500279A5 true JP2008500279A5 (https=) | 2008-03-06 |
| JP4851348B2 JP4851348B2 (ja) | 2012-01-11 |
Family
ID=34910810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554230A Expired - Fee Related JP4851348B2 (ja) | 2004-02-23 | 2005-02-17 | 抗Ａβ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070190046A1 (https=) |
| EP (1) | EP1720909B1 (https=) |
| JP (1) | JP4851348B2 (https=) |
| KR (2) | KR100889430B1 (https=) |
| CN (1) | CN1922209B (https=) |
| AT (1) | ATE534667T1 (https=) |
| AU (1) | AU2005217596B2 (https=) |
| BR (1) | BRPI0507856A (https=) |
| CA (1) | CA2556436C (https=) |
| CY (1) | CY1112162T1 (https=) |
| DK (1) | DK1720909T3 (https=) |
| EA (1) | EA009872B1 (https=) |
| ES (1) | ES2375627T3 (https=) |
| IL (1) | IL177611A (https=) |
| NO (1) | NO20064239L (https=) |
| PL (1) | PL1720909T3 (https=) |
| PT (1) | PT1720909E (https=) |
| SI (1) | SI1720909T1 (https=) |
| UA (1) | UA93181C2 (https=) |
| WO (1) | WO2005082939A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| EP1959996A2 (en) | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| TW200844110A (en) | 2007-01-11 | 2008-11-16 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's disease and other neurodementing diseases |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| BRPI0818623A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| AU2009319864A1 (en) | 2008-11-25 | 2011-07-14 | Biogen Idec Ma Inc. | Use of DR6 and P75 antagonists to promote survival of cells of the nervous system |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| US20110110942A1 (en) | 2009-11-12 | 2011-05-12 | Genentech, Inc. | Method of promoting dendritic spine density |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| CN120904322A (zh) | 2013-09-13 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JP6840774B2 (ja) | 2016-05-16 | 2021-03-10 | ザ ジェネラル ホスピタル コーポレイション | 肺上皮エンジニアリングにおけるヒト気道幹細胞 |
| US20210355138A1 (en) * | 2016-08-11 | 2021-11-18 | Eli Lilly And Company | Aminothiazinies and their use as bace1 inhibitors |
| CN118370815A (zh) | 2017-08-22 | 2024-07-23 | 渤健马萨诸塞州股份有限公司 | 含有抗β淀粉样蛋白抗体的药物组合物 |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001232A3 (en) | 1996-12-23 | 2001-02-28 | Elan Pharmaceuticals Inc San F | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| JP2003530437A (ja) * | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Ａβ４２低下物質 |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| EP2165714B1 (en) * | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
-
2005
- 2005-02-17 SI SI200531422T patent/SI1720909T1/sl unknown
- 2005-02-17 PL PL05723280T patent/PL1720909T3/pl unknown
- 2005-02-17 EA EA200601545A patent/EA009872B1/ru not_active IP Right Cessation
- 2005-02-17 DK DK05723280.3T patent/DK1720909T3/da active
- 2005-02-17 EP EP05723280A patent/EP1720909B1/en not_active Expired - Lifetime
- 2005-02-17 ES ES05723280T patent/ES2375627T3/es not_active Expired - Lifetime
- 2005-02-17 JP JP2006554230A patent/JP4851348B2/ja not_active Expired - Fee Related
- 2005-02-17 KR KR1020067016812A patent/KR100889430B1/ko not_active Expired - Fee Related
- 2005-02-17 US US10/590,411 patent/US20070190046A1/en not_active Abandoned
- 2005-02-17 WO PCT/US2005/005198 patent/WO2005082939A2/en not_active Ceased
- 2005-02-17 UA UAA200609258A patent/UA93181C2/ru unknown
- 2005-02-17 CA CA2556436A patent/CA2556436C/en not_active Expired - Fee Related
- 2005-02-17 KR KR1020087031635A patent/KR20090005410A/ko not_active Ceased
- 2005-02-17 PT PT05723280T patent/PT1720909E/pt unknown
- 2005-02-17 AU AU2005217596A patent/AU2005217596B2/en not_active Ceased
- 2005-02-17 AT AT05723280T patent/ATE534667T1/de active
- 2005-02-17 BR BRPI0507856-3A patent/BRPI0507856A/pt not_active IP Right Cessation
- 2005-02-17 CN CN2005800056858A patent/CN1922209B/zh not_active Expired - Fee Related
-
2006
- 2006-08-21 IL IL177611A patent/IL177611A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064239A patent/NO20064239L/no not_active Application Discontinuation
-
2011
- 2011-12-21 CY CY20111101276T patent/CY1112162T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500279A5 (https=) | ||
| Diller et al. | The role of the extracellular matrix (ECM) in wound healing: a review | |
| Marchioni et al. | Pulmonary stretch and lung mechanotransduction: implications for progression in the fibrotic lung | |
| Caballé-Serrano et al. | Tissue response to a porous collagen matrix used for soft tissue augmentation | |
| Babina et al. | Thymic stromal lymphopoietin promotes MRGPRX2-triggered degranulation of skin mast cells in a STAT5-dependent manner with further support from JNK | |
| Yamada et al. | Diagnostic cytokines and comparative analysis secreted from exfoliated deciduous teeth, dental pulp, and bone marrow derived mesenchymal stem cells for functional cell-based therapy | |
| Petrini et al. | Influence of nano, micro, and macro topography of dental implant surfaces on human gingival fibroblasts | |
| Dai et al. | Vascular remodeling: the multicellular mechanisms of pulmonary hypertension | |
| WO2007077217A3 (en) | Oligopeptide-free cell culture media | |
| Bateman et al. | Airway epithelium senescence as a driving mechanism in COPD pathogenesis | |
| Ghinassi et al. | Gingival response to dental implant: comparison study on the effects of new nanopored laser-treated vs. traditional healing abutments | |
| JP2004533242A5 (https=) | ||
| Loukelis et al. | Kappa-carrageenan/chitosan/gelatin scaffolds provide a biomimetic microenvironment for dentin-pulp regeneration | |
| Bonifacino et al. | Enhanced function and overexpression of metabotropic glutamate receptors 1 and 5 in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis during disease progression | |
| CO6220900A2 (es) | Forma dosificadora novedosa | |
| Zhou et al. | Fabrication of fibrin/polyvinyl alcohol scaffolds for skin tissue engineering via emulsion templating | |
| Hofer et al. | Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review | |
| Lettieri et al. | The plastic interplay between lung regeneration phenomena and fibrotic evolution: current challenges and novel therapeutic perspectives | |
| Gaddam et al. | Cystathionine-Gamma-Lyase-Derived hydrogen sulfide-regulated substance P modulates liver sieve fenestrations in Caecal ligation and puncture-induced sepsis | |
| Simko et al. | Sacubitril/Valsartan and Ivabradine Attenuate Left ventricular remodelling and dysfunction in spontaneously hypertensive rats: different interactions with the renin–angiotensin–aldosterone system | |
| Clemens et al. | Understanding antibody responses in early life: baby steps towards developing an effective influenza vaccine | |
| Haas et al. | Recovery of altered diabetic myofibroblast heterogeneity and gene expression are associated with CD301b+ macrophages | |
| Volloch et al. | Next Generation Therapeutic Strategy for Treatment and Prevention of Alzheimer’s Disease and Aging-Associated Cognitive Decline: Transient, Once-in-a-Lifetime-Only Depletion of Intraneuronal Aβ (i Aβ) by Its Targeted Degradation via Augmentation of Intra-i Aβ-Cleaving Activities of BACE1 and/or BACE2 | |
| DE60319599T8 (de) | Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit | |
| Stanford et al. | Safety, feasibility, and impact of enalapril on cardiorespiratory physiology and health in preterm infants with systemic hypertension and left ventricular diastolic dysfunction |